ProCE Banner Activity

Recent Developments and Considerations in the Care of Patients With Gynecologic Cancer

Clinical Thought

Commentary on recent developments and current considerations for managed care professionals involving the use of PARP inhibitor maintenance therapy in ovarian cancer, immunotherapy plus chemotherapy regimens in endometrial cancer, and recent antibody–drug conjugate indication updates in gynecologic cancers and solid tumors.

Released: May 30, 2024

Expiration: May 29, 2025

Share

Faculty

Laura R. Bobolts

Laura R. Bobolts, PharmD, BCOP

SVP, Clinical Strategy and Growth
OncoHealth
Pompano Beach, Florida 

Provided by

Provided by ProCE, LLC in partnership with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and GlaxoSmithKline.

AstraZeneca

GlaxoSmithKline

Partners

Clinical Care Options, LLC

ProCE Banner

Faculty Disclosure

Primary Author

Laura R. Bobolts, PharmD, BCOP

SVP, Clinical Strategy and Growth
OncoHealth
Pompano Beach, Florida 

Laura R. Bobolts, PharmD, BCOP, has no relevant financial relationships to disclose.